Authors Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N
Molecular cancer therapeutics Feb 2019
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.Authors Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G
Theranostics Jan 2019
A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.Authors Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Schneider D, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W
Frontiers in immunology Jan 2019
Editorial: Metformin: Beyond Diabetes.Authors Bost F, Rena G, Viollet B
Frontiers in endocrinology Jan 2019
Hypoxia protects against the cell death triggered by oxovanadium-galactomannan complexes in HepG2 cells.Authors Meyenberg Cunha-de Padua M, Noleto GR, de Oliveira Petkowicz CL, Cadena SMSC, Bost F, Pouysségur J, Mazure NM
Cellular & molecular biology letters Jan 2019
The metabolic modulator PGC-1α in cancer.Authors Bost F, Kaminski L
American journal of cancer research Jan 2019
Regulation of tumor-stroma interactions by the unfolded protein response.Authors Obacz J, Avril T, Rubio-Patiño C, Bossowski JP, Igbaria A, Ricci JE, Chevet E
The FEBS journal Jan 2019
Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease.Authors Luci C, Vieira E, Perchet T, Gual P, Golub R
Frontiers in immunology Jan 2019
Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.Authors Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, Roméro H, Selleri S, Béland K, Guiot M, Tremblay-Laganière C, Dicaire R, Barreiro L, Lee DA, Verhoeyen E, Haddad E
Frontiers in immunology Jan 2019
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.Authors Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G
Theranostics Jan 2019